SPARCL1 and cancer: The elevated ESTIMATE scores, abundance of naive B cells, M2 macrophages, resting mast cells, increased TMB and TIDE score, as well as the upregulation of multiple immune checkpoints in the high SPARCL1 expression subgroup, led us to speculate that SPARCL1 may play an indispensable role in shaping the immune microenvironment, which could potentially counteract its anti‐cancer effects.